Menu

NIH’s Neuroscience Institute Plans to Limit Financial Support for Well-Funded Investigators

Under a new policy, the National Institute of Neurological Disorders and Stroke will provide fewer grants to labs receiving more than $1 million in funds.

May 3, 2018
Diana Kwon

NCI, CHRIS SPIELMANN

The National Institute of Neurological Disorders and Stroke (NINDS), which is part of the National Institutes of Health (NIH), will limit the number of grants it provides to well-funded investigators, according to a new policy it announced last week (April 27).

In 2012, the NIH implemented an institutes-wide policy under which grant applications from investigators already receiving more than $1 million in funding would receive additional scrutiny. The new NINDS rules, which will apply to grants under consideration from January 2019 and beyond, will extend the stricter review to labs whose funding support would exceed $1 million after the acceptance of a pending proposal.

The policy “will allow us to fund more early stage investigators and help people who just missed the pay line [funding cutoff] and are about to drop off the radar screen,” Robert Finkelstein, the extramural research director at NINDS, tells Science.

See “Proposed NIH Grant Cap Criticized

Last year, the NIH proposed a grant cap, based on its funding metric called the Grant Support Index (GSI), for investigators who received more than three R01 grants, in order to provide more funding opportunities for early-career researchers. However, after drawing heavy criticism from the research community, the NIH decided to abandon that plan and instead created the Next Generation Researchers Initiative, a special fund for early- to mid-career investigators.

“When the GSI went away the problem of funding more investigators didn’t disappear. So something has to be done to fund more people,” Howard Garrison, director of public affairs at the Federation of American Societies for Experimental Biology, tells Science.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.